Prognostic Value of Post-Operative C-Reactive Protein-Based Inflammatory Biomarkers in Colorectal Cancer Patients: Systematic Review and Meta-Analysis
Tafirenyika Gwenzi,Anna Zhu,Petra Schrotz-King,Ben Schöttker,Michael Hoffmeister,Dominic Edelmann,Hermann Brenner
DOI: https://doi.org/10.2147/CLEP.S415171
2023-06-27
Clinical Epidemiology
Abstract:Tafirenyika Gwenzi, 1, 2 Anna Zhu, 2, 3 Petra Schrotz-King, 1 Ben Schöttker, 3 Michael Hoffmeister, 3 Dominic Edelmann, 4 Hermann Brenner 1, 3, 5, 6 1 Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, 69120, Germany; 2 Medical Faculty Heidelberg, Heidelberg University, Heidelberg, 69120, Germany; 3 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany; 4 Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany; 5 Network Aging Research, Heidelberg University, Heidelberg, 69115, Germany; 6 German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany Correspondence: Hermann Brenner, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, Heidelberg, 69120, Germany, Tel +49 6221 42 1300, Fax +49-6221 42 1302, Email Post-operative inflammation in cancer patients can be modulated by drugs and diets, but evidence on its prognostic role, which would be crucial for personalized treatment and surveillance schemes, remains rather limited. We aimed to systematically review and meta-analyse studies on the prognostic value of post-operative C-reactive protein (CRP)-based inflammatory biomarkers among patients with colorectal cancer (CRC) (PROSPERO&num: CRD42022293832). PubMed, Web of Science and Cochrane databases were searched until February 2023. Studies reporting associations between post-operative CRP, Glasgow Prognostic Score (GPS) or modified Glasgow Prognostic Score (mGPS) with overall survival (OS), CRC-specific survival (CSS) and recurrence-free survival (RFS) were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the predictor-outcome associations were pooled using R-software, version 4.2. Sixteen studies (n = 6079) were included in the meta-analyses. Elevated post-operative CRP was a predictor of poor OS, CSS and RFS compared with low CRP levels [HR (95% CI): 1.72 (1.32– 2.25); 1.63 (1.30– 2.05); 2.23 (1.44– 3.47), respectively]. A unit increase in post-operative GPS predicted poor OS [HR (95% Cl): 1.31 (1.14– 1.51)]. Moreover, a unit increase in post-operative mGPS was associated with poor OS and CSS [HR (95% Cl): 1.93 (1.37– 2.72); 3.16 (1.48– 6.76), respectively]. Post-operative CRP-based inflammatory biomarkers have a significant prognostic role for patients with CRC. Prognostic value of these easy-to-obtain routine measurements thereby seems to outperform most of the much more complex blood- or tissue-based predictors in the current focus of multi-omics-based research. Future studies should validate our findings, establish optimal time for biomarker assessment and determine clinically useful cut-off values of these biomarkers for post-operative risk-stratification and treatment-response monitoring. Keywords: C-reactive protein, survival, assess, risk-stratification, treatment-response Colorectal cancer (CRC) remains the second most common cause of cancer death worldwide despite improvements in early detection, surgical techniques, and chemoradiotherapy. 1 Prognosis most strongly depends on stage at diagnosis, with 5-year relative survival ranging from above 90% for stage I to less than 20% for stage IV cancers. 2 However, evidence on prognostic factors besides and within stages, which would be crucial for personalized treatment and surveillance schemes, remains rather limited. CRC prognosis is strongly linked to host inflammatory response at both tumor micro-environment and systemic levels. 3,4 In recent years, an increasing number of studies have reported post-treatment inflammatory blood biomarkers to be predictive of CRC outcomes. 5–12 While inflammation can be reduced by anti-inflammatory drugs 13–15 and diets with low dietary inflammation scores, 16–18 comparative and integrative evaluation of clinical relevance of post-operative inflammatory response is limited due to heterogeneity in key design features of pertinent studies, such as selection of inflammatory markers, definition of cut-offs, timing of blood draw, length of follow-up, specific survival endpoints assessed and covariates adjusted for. The most widely reported inflammatory marker in cancer research is C-reactive protein (CRP), whose analysis in cancer monitoring is routine, relatively cheap, and simple. 19 Serum CRP has been reported as a useful CRC prognosticator, either alone or in combination with albumin as is the case with the Glasgow Prognostic Score (GPS) and the modified Glasgow -Abstract Truncated-
public, environmental & occupational health